<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555438</url>
  </required_header>
  <id_info>
    <org_study_id>0701017</org_study_id>
    <secondary_id>2007-001048-32</secondary_id>
    <nct_id>NCT00555438</nct_id>
  </id_info>
  <brief_title>Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.</brief_title>
  <acronym>PROPICE</acronym>
  <official_title>Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux,in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. PROPICE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fondaparinux is an antithrombotic agent having already received a regulatory approval by the
      European Authorities in venous thromboembolic event prevention after major orthopaedic
      surgery, as total hip replacement (THR), total knee replacement (TKR), hip fracture (HF). The
      bleeding risk associated with this prescription is highly related to renal function evaluated
      by creatinin clearance (CrCl). In order to reduce the bleeding risk, it has been proposed to
      prescribe fondaparinux 1.5 mg/day in patients with a CrCl between 20 and 50ml/mn instead of
      2.5mg/day (European MMA). In the meantime, this approval is essentially based on simulated
      pharmakinetic data without any support of clinical data.

      prospective, multicentre, open-label study evaluating the safety profile of fondaparinux 1.5
      mg/day, subcutaneously administered, in patients with a renal impairment defined by a CrCl
      between 20 and 30 ml/min and undergoing a major orthopaedic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fondaparinux 1.5mg/day subcutaneously administered during post-surgery 1 to 10 days with the
      1st treatment administration performed 6 to 8 hours after the end of surgery.

      Screening visit : &gt; 7 days before inclusion visit if THR and TKR Inclusion visit : day of
      surgery Visits with blood drawing: 3 visits scheduled during 1 to 10 days of treatment period
      Study end of treatment visit: D1 to D10 Study end visit: 1 month ± 15 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Major Bleedings Between Day 1 and Day 10.</measure>
    <time_frame>10 day</time_frame>
    <description>evaluate between Day 1 and Day 10, the number of patients under study treatment who has affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of &gt;2 units of packed red blood cells or was associated with a fall in hemoglobin &gt;20 g/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Major Bleedings at 1 Month ± 5 Days.</measure>
    <time_frame>45 day</time_frame>
    <description>evaluate the number of patients affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of &gt;2 units of packed red blood cells or was associated with a fall in hemoglobin &gt;20 g/L at 1 month ± 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism Between Day 1 and Day 10</measure>
    <time_frame>10 days</time_frame>
    <description>Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) between Day 1 and Day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism at 1 Month ± 5 Days</measure>
    <time_frame>at 1 month ± 5</time_frame>
    <description>Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) at 1 month ± 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death at 1 Month ± 5 Days</measure>
    <time_frame>1 month ± 5 days</time_frame>
    <description>Evaluate the total number of death at 1 month ± 5 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Major Orthopaedic Surgery and Renal Impairment</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fondaparinux 1.5 mg/day</intervention_name>
    <description>Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • age &gt; 18 years old,

               -  undergoing a major orthopaedic surgery (THR, TKR, HF) whatever procedure
                  techniques are used, 1st indication or 2nd indication,

               -  requiring an antithrombotic prophylaxis,

               -  presenting a renal impairment defined by a creatinin clearance (CrCl) between 20
                  and 50 ml/min calculated by Cockcroft and Gault's formula,

               -  having signed the inform consent form.

        Exclusion Criteria:

          -  contra-indications to fondaparinux,

          -  history of heparin inducted thrombopenia (HIT),

          -  platelets &lt; 100 g/l.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MISMETTI Patrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GARANGER Thierry</name>
      <address>
        <city>Agen</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHARRET Françoise</name>
      <address>
        <city>Annonay</city>
        <zip>07100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BONNEMAISON Julie</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BELLOUCIF Sadek</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZTARCK François</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEGOIX Michel</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSSET Sylvain</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCHOEFFLER Pierre</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LETOURNEAU Bernard</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TISSIER Dominique</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEMANISSIER Denis</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHAMBON Françoise</name>
      <address>
        <city>Lyon</city>
        <zip>69006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BEGOU Gérard</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAPDEVILLA Xavier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PERON Alain</name>
      <address>
        <city>Nantes</city>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GAERTNER Elisabeth</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RIPART Jacques</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHEVALEREAUD Erick</name>
      <address>
        <city>Niort</city>
        <zip>79006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LANGERON Olivier</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RABUEL Christophe</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAZUIRE Elisabeth</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THERY Philippe</name>
      <address>
        <city>Poitiers</city>
        <zip>86035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BARRE Jeanne</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIGNOT Sophie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MARTIN</name>
      <address>
        <city>SAINt-ETIENNE</city>
        <zip>42 055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAYLOT Denis</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUVERGER Daniel</name>
      <address>
        <city>Saint-saulve</city>
        <zip>59880</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FUZIER Régis</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COUVRET Claude</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2007</study_first_submitted>
  <study_first_submitted_qc>November 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2007</study_first_posted>
  <results_first_submitted>September 15, 2010</results_first_submitted>
  <results_first_submitted_qc>October 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2010</results_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pr Patrick MISMETTI</name_title>
    <organization>Centre Hospitalier Universitaire de Saint Etienne</organization>
  </responsible_party>
  <keyword>major orthopaedic surgery</keyword>
  <keyword>venous thromboembolic events prevention</keyword>
  <keyword>renal impairment</keyword>
  <keyword>Arixtra</keyword>
  <keyword>anti-Xa activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>patients have been included between june 2007 and june 2008 in public and private French hospitals</recruitment_details>
      <pre_assignment_details>Nine patients received no study drug due to immediate postoperative death (n=1), consent withdrawal (n=2), use of another thromboprophylactic agent (n=2), surgery change or cancellation (n=2), and CrCl &gt;50 mL/min just before surgery (n=2)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fondaparinux 1.5 mg/l</title>
          <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>10 Days Post-operative</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="442"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="438">438 patients attended the day 10 visit (four patients died during hospitalization)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Between 10 Days and 30 Days Postoperativ</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="438"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fondaparinux 1.5 mg/l</title>
          <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="442"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.4" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Major Bleedings Between Day 1 and Day 10.</title>
        <description>evaluate between Day 1 and Day 10, the number of patients under study treatment who has affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of &gt;2 units of packed red blood cells or was associated with a fall in hemoglobin &gt;20 g/L.</description>
        <time_frame>10 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fondaparinux 1.5 mg/l</title>
            <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Major Bleedings Between Day 1 and Day 10.</title>
          <description>evaluate between Day 1 and Day 10, the number of patients under study treatment who has affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of &gt;2 units of packed red blood cells or was associated with a fall in hemoglobin &gt;20 g/L.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Major Bleedings at 1 Month ± 5 Days.</title>
        <description>evaluate the number of patients affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of &gt;2 units of packed red blood cells or was associated with a fall in hemoglobin &gt;20 g/L at 1 month ± 5 days.</description>
        <time_frame>45 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fondaparinux 1.5 mg/l</title>
            <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Major Bleedings at 1 Month ± 5 Days.</title>
          <description>evaluate the number of patients affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of &gt;2 units of packed red blood cells or was associated with a fall in hemoglobin &gt;20 g/L at 1 month ± 5 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism Between Day 1 and Day 10</title>
        <description>Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) between Day 1 and Day 10.</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fondaparinux 1.5 mg/l</title>
            <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism Between Day 1 and Day 10</title>
          <description>Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) between Day 1 and Day 10.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism at 1 Month ± 5 Days</title>
        <description>Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) at 1 month ± 5 days.</description>
        <time_frame>at 1 month ± 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fondaparinux 1.5 mg/l</title>
            <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism at 1 Month ± 5 Days</title>
          <description>Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) at 1 month ± 5 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death at 1 Month ± 5 Days</title>
        <description>Evaluate the total number of death at 1 month ± 5 days</description>
        <time_frame>1 month ± 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fondaparinux 1.5 mg/l</title>
            <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Death at 1 Month ± 5 Days</title>
          <description>Evaluate the total number of death at 1 month ± 5 days</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fondaparinux 1.5 mg/l</title>
          <description>patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" events="38" subjects_affected="2" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation paroxysmal</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>cardio-respiratory failure</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Infarction mesenteric</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>gastrointestinal disorder NOS</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Gastroduodenal hemorrhage</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>proctorrhagia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Small intestine obstruction</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction NOS</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>general physical health deterioration</sub_title>
                <counts group_id="E1" events="38" subjects_affected="2" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diarrhea, Clostridium difficile</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>septic shock</sub_title>
                <counts group_id="E1" events="38" subjects_affected="2" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>incision site infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="3" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>prosthesis fracture</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>incision site hematoma</sub_title>
                <counts group_id="E1" events="38" subjects_affected="3" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>anemia postoperative</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>incision site inflammation</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>femoral greater trochanter fracture</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Fracture of neck of femur</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis postoperative</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>transient cerebral ischemia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>ischemic strocke</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratort insufficiency</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute pulmonary edaema</sub_title>
                <counts group_id="E1" events="38" subjects_affected="2" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title>Pneumothorax NOS</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>mesenteric ischemia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="1" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="442"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr patrick MISMETTI</name_or_title>
      <organization>CHU SAINT-ETIENNE</organization>
      <phone>33(1)477127788</phone>
      <email>patrick.mismetti@chu-st-etienne.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

